Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:QNCX NASDAQ:RNTX NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.75$1.79$1.41▼$4.34$74.64M0.151.44 million shs471,963 shsQNCXQuince Therapeutics$17.85-0.1%$19.41$15.10▼$909.98$17.49M1.438,349 shs14,924 shsRNTXRein Therapeutics$0.79$0.97$0.76▼$2.18$67.69M1.35437,778 shs342,088 shsSCLXScilex$6.84$7.59$4.20▼$34.27$58.07M1.66201,865 shs128,884 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+2.34%0.00%-10.26%+3.55%QNCXQuince Therapeutics0.00%-5.46%-5.41%-30.81%-95.18%RNTXRein Therapeutics0.00%-8.21%-18.52%-46.89%-45.80%SCLXScilex0.00%-18.96%-3.80%-0.58%-42.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.75$1.79$1.41▼$4.34$74.64M0.151.44 million shs471,963 shsQNCXQuince Therapeutics$17.85-0.1%$19.41$15.10▼$909.98$17.49M1.438,349 shs14,924 shsRNTXRein Therapeutics$0.79$0.97$0.76▼$2.18$67.69M1.35437,778 shs342,088 shsSCLXScilex$6.84$7.59$4.20▼$34.27$58.07M1.66201,865 shs128,884 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+2.34%0.00%-10.26%+3.55%QNCXQuince Therapeutics0.00%-5.46%-5.41%-30.81%-95.18%RNTXRein Therapeutics0.00%-8.21%-18.52%-46.89%-45.80%SCLXScilex0.00%-18.96%-3.80%-0.58%-42.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 2.67Moderate Buy$7.50328.57% UpsideQNCXQuince Therapeutics 2.20Hold$690.003,765.55% UpsideRNTXRein Therapeutics 2.25Hold$6.00658.25% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest QNCX, RNTX, GANX, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026RNTXRein Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/17/2026RNTXRein Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026GANXGain Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/30/2026GANXGain Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/29/2026QNCXQuince Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2026RNTXRein Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026QNCXQuince Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/24/2026QNCXQuince Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.006/23/2026QNCXQuince Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$80.006/23/2026QNCXQuince Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$80.006/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,492.75N/AN/A$0.48 per share3.65QNCXQuince TherapeuticsN/AN/AN/AN/A($128.18) per shareN/ARNTXRein TherapeuticsN/AN/A$0.06 per share13.84($1.07) per shareN/ASCLXScilex$30.25M1.92N/AN/A($24.94) per share-0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)QNCXQuince Therapeutics-$83.98M-$212.40N/AN/AN/AN/AN/A-67.99%8/11/2026 (Estimated)RNTXRein Therapeutics-$49.87M-$1.90N/AN/AN/AN/AN/A-68.14%N/ASCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)Latest QNCX, RNTX, GANX, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026GANXGain Therapeutics-$0.14N/AN/AN/A$0.03 millionN/A8/11/2026Q2 2026QNCXQuince Therapeutics-$25.40N/AN/AN/AN/AN/A5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/15/2026Q1 2026RNTXRein Therapeutics-$0.49-$0.19+$0.30-$0.19N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/11/2026Q1 2026QNCXQuince Therapeutics-$26.00-$0.59+$25.41$57.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.024.694.69QNCXQuince TherapeuticsN/A2.922.92RNTXRein TherapeuticsN/A0.400.40SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%QNCXQuince Therapeutics30.75%RNTXRein Therapeutics90.89%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics4.15%QNCXQuince Therapeutics7.10%RNTXRein Therapeutics1.50%SCLXScilex4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableQNCXQuince Therapeutics60980,000909,000OptionableRNTXRein Therapeutics985.54 million84.26 millionN/ASCLXScilex808.49 million8.11 millionNo DataQNCX, RNTX, GANX, and SCLX HeadlinesRecent News About These CompaniesScilex Announces Strategic Sale of Vivasor Preferred SharesJuly 22, 2026 | tipranks.comScilex Holding CompanyJuly 16, 2026 | cnn.comScilex (NASDAQ:SCLX) Trading Up 0.8% - Here's What HappenedJuly 10, 2026 | marketbeat.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for ...July 7, 2026 | finance.yahoo.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 7, 2026 | globenewswire.comScilex Holding Company (SCLX) Stock Surges on $100M Investment Proposal from iHoldingJuly 6, 2026 | blockonomi.comScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026July 6, 2026 | globenewswire.comScilex shares jump after securing $100 million strategic investment proposal (SCLX)July 6, 2026 | msn.comWhat's going on with Scilex Holding stock Monday?July 6, 2026 | msn.comScilex secures major growth capital equity investmentJuly 6, 2026 | tipranks.comScilex Holding Company Announces Binding Term Sheet for $100 Million Strategic Investment from iHolding Group LLPJuly 6, 2026 | quiverquant.comQScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 6, 2026 | globenewswire.comScilex Pursues Major Bitcoin Acquisition via Term SheetJune 29, 2026 | tipranks.comScilex Stockholders Approve Director Election and Equity PlanJune 24, 2026 | tipranks.comScilex Holding Company to List Dream Bowl Tokens on Biconomy Exchange Starting June 23, 2026June 16, 2026 | quiverquant.comQScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026June 16, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders ...June 12, 2026 | finance.yahoo.comScilex Holding Company Announces Dividend Payment Date for Semnur Pharmaceuticals Common StockJune 12, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 12, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 5, 2026 | theglobeandmail.comScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNCX, RNTX, GANX, and SCLX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.75 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Quince Therapeutics NASDAQ:QNCX$17.85 -0.01 (-0.06%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$17.52 -0.33 (-1.82%) As of 07/24/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Rein Therapeutics NASDAQ:RNTX$0.79 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.79 0.00 (-0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Scilex NASDAQ:SCLX$6.84 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.96 +0.12 (+1.78%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware This Tiny AI Supplier Could Be More Important Than the Chipmakers Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Meta Earnings Put AI Spending and Ad Growth Back in Focus These 3 AI Winners Don’t Sell the Tech—They Use It Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
